The spotlight of this year's event is "From Bench to Practice", a theme which brings together the work of basic science and everyday clinical medicine. "Only through the concerted efforts of both disciplines can we continue to bring further improvements to patient care," says ESC President Professor Michel Komajda. "By choosing translational science as its 2012 congress spotlight, the ESC is encouraging critical discussion of new techniques and their rapid transfer into clinical practice."
ESC Congress 2012 will take place at the ICM Messe-München, Messegelände, 81823, Munich, Germany.
Journalists planning to attend are invited to register via the congress press section of the ESC website.
ESC Congress 2012 in Munich is expected to attract more than 30,000 registered participants (as well as 750 registered press), making it the largest medical meeting in the world, and a guaranteed source of important news stories. In cardiology, says Professor Komajda, the ESC Congress has indisputably become the number one international event, reflected in the high number of submissions from non-European countries and in participant registrations.
This year's congress will feature:
- Five days of scientific sessions
- More than 4,000 presentations of new studies selected from 10,000+ abstracts submitted
- 17 Hot Line presentations, featuring the first results from major clinical trials
- Updates from earlier landmark trials
- 200 exhibiting companies and 70 sponsored sessions
Press support in Munich will be concentrated on three press conferences per day (from Sunday to Tuesday), which are led each morning by the late-breaking results of clinical trials selected for Hot Line sessions. These are studies (many of which are reported simultaneously and under embargo in the leading medical journals) whose outcomes will shape the treatment of cardiovascular disease in the years to come, and which traditionally provide front-page news across the world. This year, Hot Line sessions will feature results from major trials in coronary intervention, heart failure, coronary artery disease and arrhythmias.
Included among them are results from the phase III TRILOGY-ACS study, the largest randomised trial of prasugrel and clopidogrel in medically managed patients with acute coronary syndromes (which include unstable angina and heart attack). ACS patients managed medically and without acute intervention represent a large and relatively understudied patient group. Also scheduled for presentation are new results from the international PURE study of cardiovascular risk factor prevalence among more than 150,000 subjects in 17 countries according to gender and economic status.
The press conference programme will also feature new developments derived from smaller studies submitted as abstracts and collected under eight themed headings:
- New approaches to diagnosis and treatment in heart failure (genetics, spinal cord stimulation)
- Women (obesity and atrial fibrillation, stroke risk)
- Smoking (in adolescents, effect of smoking bans, electronic cigarette)
- Sudden cardiac death in sports (genetics of family members, cost of screening)
- New risk factor findings in cardiovascular disease (insomnia, energy drinks)
- Renal denervation in hypertension (follow-up, outcomes)
- Transcatheter implantation of prosthetic aortic valves (sex differences, quality of life)
- Prevention and outcomes in cardiac ischaemia (effect of aspirin, stroke)
Press releases in support of the press conferences will be issued under embargo a few days in advance. In addition, press releases will be available on six new ESC Clinical Practice Guidelines - in particular on the prevention of cardiovascular disease - and on updates from the ESC's own observational registries.
Accredited journalists can make use of a well serviced press room, with wifi and work space available.
In the meantime, we encourage you to mark the dates in your diary, and to contact the ESC press office for further information.
Provided by European Society of Cardiology
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.